Sigyn Therapeutics Secures $61.5K Through Highly Dilutive Convertible Notes

summarizeSummary

Sigyn Therapeutics raised $61,500 via convertible notes with highly dilutive terms, including a 35% discount to the lowest traded price, indicating financial distress.

check_boxKey Events

• Convertible Note Agreements Executed

  Sigyn Therapeutics entered into three separate one-year Convertible Note Purchase Agreements on February 6 and February 12, 2026, with Brio Capital Master Fund, Ltd., Osher Capital Partners, LLC, and Lambda Venture Partners, LLC.

• Capital Raise Details

  The agreements resulted in total gross proceeds of $61,500 for the company. The notes bear an 8% annual interest rate.

• Highly Dilutive Conversion Terms

  The notes are convertible into common stock at a 35% discount to the lowest traded price of the company's common shares during the twenty trading days immediately prior to the conversion notice, indicating a highly dilutive financing structure.

• Use of Proceeds

  The proceeds from these convertible notes are designated for general working capital purposes.

auto_awesomeAnalysis

Sigyn Therapeutics, a nano-cap company currently trading at its 52-week low, has secured $61,500 in gross proceeds through three convertible note purchase agreements. While this capital provides immediate working capital, the terms are highly unfavorable for existing shareholders. The notes are convertible into common stock at a 35% discount to the lowest traded price during the 20 trading days prior to conversion. This aggressive discount mechanism allows investors to convert at progressively lower prices, leading to substantial dilution and significant downward pressure on the stock. This financing structure highlights the company's distressed financial position and its high cost of capital, signaling potential challenges for long-term shareholder value.